Inhibition of erythrocyte selenium-glutathione peroxidase by auranofin analogues and metabolites

Biochemical Pharmacology

Volumn 55, Issue 8, 1998, Pages 1291-1299

  Roberts, Jacqueline R ^a   Shaw III, C Frank ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Auranofin; bis(glutathionato)gold(I); Erythrocytes; Gold(1) thioglucose; Inhibition constants; Selenium glutathione peroxidase; Serum albumin

Indexed keywords

AURANOFIN; AURANOFIN DERIVATIVE; AUROTHIOGLUCOSE; DRUG METABOLITE; GOLD COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTHRITIS; ARTICLE; CATTLE; DRUG ACCUMULATION; DRUG MECHANISM; ENZYME INACTIVATION; ERYTHROCYTE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIRHEUMATIC AGENTS; AURANOFIN; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME REPRESSION; ERYTHROCYTES; GLUTATHIONE PEROXIDASE; HUMANS; MALE; SERUM ALBUMIN;

EID: 0032523001     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00634-5     Document Type: Article

References (31)

1. 9PS. Cryst Struct Commun. 9:1980;679-686.
2. Herrlinger JD, Alsen C, Beress R, Hecker U, Weikert W. Distribution of gold in serum erythrocytes and white blood cells after in vitro incubation and during chrysotherapy with different gold compounds. J Rheumatol. 9:1982;81-89.
3. Walz DT, DiMartino MJ, Griswold DE, Intoccia AP, Flanagan TL. Biologic actions and pharmacokinetic studies of auranofin. Am J Med. 74:1983;90-108.
4. Shaw CF III, Isab AA, Coffer MT, Mirabelli CK. Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathione-gold-albumin metabolite. Biochem Pharmacol. 40:1990;1227-1234.
5. Stadtman TC. Selenocysteine. Annu Rev Biochem. 65:1996;83-100.
6. Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem. 229:1957;189-197.
7. Flohé L, Loschen G, Günzler WA, Eichele E. Glutathione peroxidase, V. The kinetic mechanism. Hoppe-Seyler's Z Physiol Chem. 353:1972;987-999.
8. Sadler PJ. The comparative evaluation of the physical and chemical properties of gold compounds. J Rheumatol. 9:1982;71-78.
9. Chaudiere J, Tappel AL. Interaction of gold(I) with the active site of selenium-glutathione peroxidase. J Inorg Biochem. 20:1984;313-325.
10. Chaudiere J, Wilhelmsen EC, Tappel AL. Mechanism of selenium-glutathione peroxidase and its inhibition by mercaptocarboxylic acids and other mercaptans. J Biol Chem. 259:1984;1043-1050.
11. Chaudiere J, Ph.D. Dissertation. University of California, Davis, 1983.
12. Hu M-L, Dillard CJ, Tappel AL. Aurothioglucose effect on sulfhydryls and glutathione-metabolizing enzymes In vivo inhibition of selenium-dependent glutathione peroxidase . Res Commun Chem Pathol Pharmacol. 59:1988;147-160.
13. Baker MA, Dillard CJ, Tappel AL. Effect of gold on selenium and glutathione peroxidase activities in rat tissues. Drug Nutr Interact. 3:1985;141-152.
14. Baker MA, Tappel AL. Effect of gold thioglucose on subcellular selenium distribution in liver and kidney. Biol Trace Element Res. 9:1986;113-123.
15. Hormann A, Ph.D. Dissertation. University of Wisconsin-Milwaukee, 1988.
16. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 70:1967;158-169.
17. 3PO formation . J Inorg Biochem. 30:1987;177-187.
18. Dixon M. The determination of enzyme inhibitor constants. Biochem J. 55:1953;170-175.
19. Baker MA, Tappel AL. Effects of ligands on gold inhibition of selenium glutathione peroxidase. Biochem Pharmacol. 35:1986;2417-2422.
20. Shaw CF III. The protein chemistry of anti-arthritic gold(I) thiolates and related complexes. Comments Inorg Chem. 8:1989;233-267.
21. 3PAuCl. Inorg Chem. 25:1986;333-339.
22. Intoccia AP, Flanagan TL, Walz DT, Gutzait L, Swagdis JE, Flagiello J, Hwang BY-H, Dewey RH, Noguchi H. Pharmacokinetics of auranofin in animals. J Rheumatol. 9:1982;90-98.
23. Razi MT, Otiko G, Sadler PJ. Ligand exchange reactions of gold drugs in model systems and in red cells. Am Chem Soc Symp Ser. 209:1983;371-384.
24. 31P nuclear magnetic resonance studies of human blood . J Inorg Biochem. 12:1980;317-322.
25. Shaw CF III. Inorganic and biological aspects of ligand exchange at gold(I). Sutton BM, Franz RG. Bioinorganic Chemistry of Gold Coordination Compounds. 1983;98-123 Smith Kline and French Laboratories, Philadelphia.
26. 31P NMR chemical shift Gold affinity correlation to hemoglobin-gold binding and the first interprotein gold transfer reaction . J Am Chem Soc. 110:1988;729-734.
27. Malik NA, Otiko G, Razi MT, Sadler PJ. NMR studies on ligand exchange and redox reactions of auranofin in vitro and in red cells. Sutton BM, Franz RG. Bioinorganic Chemistry of Gold Coordination Compounds. 1983;82-97 Smith Kline and French Laboratories, Philadelphia.
28. 17O in the presence of bovine serum albumin An in vitro model for auranofin metabolism . Inorg Chem. 27:1988;3406-3409.
29. Elder RC, Jones WB, Zhao S, Dorsey JG, Tepperman K. Myochrysine solution structure and reactivity. Metal Based Drugs. 1:1994;363-374.
30. Snyder RM, Mirabelli CK, Crooke ST. Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem Pharmacol. 35:1986;923-932.
31. Crooke ST, Snyder RM. The cellular and molecular pharmacology of auranofin and related gold complexes. Scand J Rheumatol Suppl. 63:1986;1-18.